SARS-CoV-2 exploits cellular RAD51 to promote viral propagation: implication of RAD51 inhibitor as a potential drug candidate against COVID-19.

Pham, Thuy X; Huynh, Trang T X; Choi, Jiwon; Lee, Jae-Bong; Park, Seok-Chan; Kim, Bumseok; Lim, Yun-Sook; Hwang, Soon B

Pham, Thuy X; Huynh, Trang T X; Choi, Jiwon; Lee, Jae-Bong; Park, Seok-Chan; Kim, Bumseok; Lim, Yun-Sook; Hwang, Soon B.

Affiliation

Pham TX; Laboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Jeonbuk National University, Iksan, South Korea.
Huynh TTX; Laboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Jeonbuk National University, Iksan, South Korea.
Choi J; College of Pharmacy, Dongduk Women's University, Seoul, South Korea.
Lee J-B; Korea Zoonosis Research Institute, Jeonbuk National University, Iksan, South Korea.
Park S-C; Laboratory of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
Kim B; Laboratory of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
Lim Y-S; Laboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Jeonbuk National University, Iksan, South Korea.
Hwang SB; Laboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Jeonbuk National University, Iksan, South Korea.

J Virol ; 97(12): e0173723, 2023 Dec 21.

Article de En | MEDLINE | ID: mdl-38051260

Sujet(s)
Mots clés

COVID-19; RAD51; RAD51 inhibitor; SARS-CoV-2; therapeutic agent

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: SARS-CoV-2 / COVID-19 Limites: Humans Langue: En Journal: J Virol Année: 2023 Type de document: Article Pays d'affiliation: Corée du Sud Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google